Circulating ADAMTS13 Levels Are Associated with an Increased Occurrence of Obstructive Sleep Apnea

Dis Markers. 2022 Mar 29:2022:1504137. doi: 10.1155/2022/1504137. eCollection 2022.

Abstract

Background and aims: Obstructive sleep apnea (OSA) is strongly associated with obesity, metabolic diseases, coronary artery disease (CAD), stroke, hypertension, and other disorders. This study assessed the relationship between circulating a disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13 (ADAMTS13) levels and the presence of OSA.

Materials and methods: This cross-sectional study included a total of 223 patients. We used a powerful high-throughput multiplexed immunobead-based assay to detect circulating levels of ADAMTS13. The associations between circulating ADAMTS13 levels and OSA were evaluated by multivariate logistic regression analysis.

Results: Circulating ADAMTS13 levels were significantly elevated in patients with OSA compared with controls (0.8 vs. 2.7 μg/mL, respectively, P < 0.001). After adjusting for confounding factors, circulating ADAMTS13 levels were significantly independently associated with the presence of OSA (odds ratio = 9.96, 95% confidence interval (CI) =4.11-24.13, P < 0.001). Furthermore, circulating ADAMTS13 levels showed discriminatory accuracy in assessing the presence of OSA (area under the curve: 0.87, 95% CI 0.81-0.93, P < 0.001).

Conclusion: Circulating ADAMTS13 levels were significantly correlated with the presence of OSA. ADAMTS13 may therefore function as a novel biomarker for monitoring the development and progression of OSA.

MeSH terms

  • ADAMTS13 Protein* / blood
  • Biomarkers / blood
  • Coronary Artery Disease* / complications
  • Cross-Sectional Studies
  • Humans
  • Odds Ratio
  • Risk Factors
  • Sleep Apnea, Obstructive* / diagnosis

Substances

  • Biomarkers
  • ADAMTS13 Protein
  • ADAMTS13 protein, human